I report on the Swiss pharmaceutical industry and healthcare topics such as access to medicine, biomedical innovation, and the impact of diseases like cancer.
I grew up just outside San Francisco and studied international affairs with a focus on development economics and healthcare policy. Prior to joining SWI swissinfo.ch in 2018, I was a freelance journalist and a researcher on business and human rights.
Explainer: Why US health funding cuts are rattling Swiss science
This content was published on
The Trump administration has upended funding by the National Institutes of Health. What does it mean for biomedical research in Switzerland?
Swiss regulator and media clash over weight-loss drugs
This content was published on
Swissmedic has taken legal action against media for alleged unauthorised advertising of weight-loss drugs. Swiss media say this is censorship.
What lies ahead for Switzerland: an economic outlook for 2025
This content was published on
Solid growth prospects, the search for a more efficient food industry, uncertainty for the pharma sector: a look at what the upcoming year has in store for the Swiss economy.
Corporate efforts to expand access to medicine stumble
This content was published on
Swiss firm Novartis tops the Access to Medicine Index for the first time. But the pharma industry still lags in making their medicine available to the poorest.
Trump presidency to test public trust in Big Pharma
This content was published on
A second Trump presidency risks eroding public trust in the pharmaceutical industry if science, trade and public health are sidelined.
This content was published on
Swiss pharma giant Roche is the latest company to refocus its R&D investment on diseases like obesity that weigh heavily on healthcare budgets.
Medicines regulators weigh hope and hype with new Alzheimer’s drugs
This content was published on
Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision won’t be easy.
This content was published on
Sex and gender are rarely considered in drug development. There’s now a movement, including in Switzerland, to change this.
This content was published on
Japan is increasingly being overlooked by international drugmakers when launching new medicine. Now, the government is fighting back.
Fiasco for democracy? Switzerland miscalculates by billions
This content was published on
Swiss politicians warn a series of calculation errors is endangering public trust in one of the most trusted governments in the world.
This content was published on
Sales of counterfeit drugs are booming around the world, putting thousands of lives at risk. Why is it so hard to stem the tide of fake medicine?
This content was published on
Swiss Post is one of the most lauded institutions in Switzerland, which is why efforts to reinvent it face some scepticism.
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
